The anti-CD138 antibody-drug conjugate (ADC), indatuximab ravtansine (BT062), had an ORR of 11%, with 41% achieving SD, in 27 patients with relapse/refractory MM in a phase I study [197]. The gene discussed is SDC1; the disease is Miyoshi myopathy.